Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Sekisui Diagnostics

For 40 years SEKISUI Diagnostics has been committed to providing innovative medical diagnostics to physicians and lab... read more Featured Products: More products

Download Mobile App




COVID-19 and Flu Combo Test Launches With FDA Clearance

By LabMedica International staff writers
Posted on 28 Oct 2026

Overlapping symptoms of COVID-19 and influenza can create diagnostic uncertainty, particularly in urgent and point-of-care settings. More...

Rapid differentiation from a single specimen can streamline triage and support timely treatment decisions, making multiplex antigen testing useful for identifying multiple respiratory viruses in one workflow. A new combo test applies this approach to detect and differentiate SARS-CoV-2 and influenza A/B at the point of care using a single anterior nasal swab.

Sekisui Diagnostics (Burlington, MA, USA) has launched the 510(k)-cleared OSOM COVID-19/Flu A&B Combo Test for professional healthcare settings. Manufactured in the United States, the assay is CLIA-waived for point-of-care use. Its introduction expands the company’s OSOM portfolio of rapid diagnostic solutions for clinical environments where timely results are needed to support patient care.

The combo test uses a lateral flow immunochromatographic assay for the qualitative detection and differentiation of influenza A and influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen. It analyzes anterior nasal swab specimens collected directly from individuals with signs and symptoms of respiratory tract infection. By combining these targets in a single cartridge, the assay enables simultaneous detection of three pathogens while retaining a simple specimen collection process and familiar point-of-care workflows.

The test’s 510(k) clearance and CLIA-waived status support its operation in point-of-care settings. To support quality control within these workflows, it incorporates QC Inside, a feature designed to eliminate separate quality control costs and provide two additional patient tests for external quality control at no charge. With COVID-19 and influenza continuing to cause overlapping symptoms, the company notes that this multiplex approach can help clinicians identify and differentiate multiple respiratory viruses from a single patient sample, supporting timely clinical decisions.

“With the Emergency Use Authorization ending, we know it is extremely important to continue to supply the market with the tools needed to diagnose respiratory infections quickly and accurately. We are pleased to be able to offer new customers and transition existing customers to a 510(k)-cleared alternative as we enter the season, so they are well prepared before the termination takes effect,” said Erica Blight, VP Strategy & Growth.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.